Facial dyskinesia: a 16-year follow-up study.
The 109 female survivors of a mental hospital population surveyed in 1965 for facial dyskinesia were followed up 16 years later. The 99 survivors with non-organic brain syndromes were analysed. Prevalence of dyskinesia had risen from 18.4% to 46.5% during follow-up and its development was significantly associated with neuroleptic dosage. Enlarged ventricles on brain scans were significantly associated with dyskinesia, cognitive impairment and neuroleptic prescribing.
McClelland
H A
HA
St Nicholas Hospital, Newcastle upon Tyne.
Metcalfe
A V
AV
Kerr
T A
TA
Dutta
D
D
Watson
P
P
D000341:Affective Disorders, Psychotic / Q000188:drug therapy / Q000523:psychology; D000368:Aged; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001921:Brain / Q000473:pathology; D002746:Chlorpromazine / Q000008:administration & dosage / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004409:Dyskinesia, Drug-Induced / Q000209:etiology*; D005152:Facial Muscles / Q000187:drug effects*; D005260:Female; D005476:Fluphenazine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D005500:Follow-Up Studies; D006801:Humans; D019965:Neurocognitive Disorders / Q000188:drug therapy / Q000523:psychology; D009460:Neurologic Examination; D009483:Neuropsychological Tests; D011618:Psychotic Disorders / Q000188:drug therapy / Q000523:psychology; D012307:Risk Factors; D012559:Schizophrenia / Q000188:drug therapy; D012565:Schizophrenic Psychology; D014057:Tomography, X-Ray Computed
D014150:Antipsychotic Agents; C011825:fluphenazine depot; D005476:Fluphenazine; D002746:Chlorpromazine